LSL Pharma Group Inc.
LSL.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -1.22M | -1.50M | -1.90M | -5.68M | -7.56M |
| Total Depreciation and Amortization | 939.70K | 938.90K | 901.10K | 837.50K | 876.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.06M | 1.04M | 757.90K | 3.12M | 3.66M |
| Change in Net Operating Assets | -3.05M | -4.49M | -3.69M | -4.24M | -3.98M |
| Cash from Operations | -2.27M | -4.01M | -3.93M | -5.96M | -7.00M |
| Capital Expenditure | -1.33M | -592.60K | -84.90K | 230.70K | -59.30K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -1.56M | -1.54M | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -524.20K | -420.40K | -279.40K | -189.60K | -232.50K |
| Cash from Investing | -3.42M | -2.55M | -364.30K | 41.00K | -291.90K |
| Total Debt Issued | 3.53M | 4.72M | 5.11M | 4.25M | 7.09M |
| Total Debt Repaid | -1.64M | -846.40K | -32.40K | -2.45M | -3.32M |
| Issuance of Common Stock | 8.23M | 7.27M | 1.99M | 9.46M | 9.46M |
| Repurchase of Common Stock | -100.00 | -100.00 | -100.00 | -100.00 | -350.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.20M | -2.48M | -2.07M | -3.27M | -3.15M |
| Cash from Financing | 5.82M | 6.39M | 3.71M | 5.92M | 7.21M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 140.20K | -174.50K | -581.80K | 100.00 | -87.70K |
